MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials
Related News

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali

Phase 3
Completed
Conditions
Infections, Streptococcal
Interventions
Biological: Pneumococcal vaccine GSK1024850A
First Posted Date
2009-09-28
Last Posted Date
2018-12-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
218
Registration Number
NCT00985465
Locations
🇲🇱

GSK Investigational Site, Bamako, Mali

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination

Phase 2
Completed
Conditions
Infections, Streptococcal
Interventions
Biological: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)
Biological: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)
Biological: Pneumococcal vaccine GSK2189242A (formulation 1)
Biological: Pneumococcal vaccine GSK2189242A (formulation 2)
Biological: Pneumococcal vaccine GSK1024850A
First Posted Date
2009-09-28
Last Posted Date
2020-11-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
257
Registration Number
NCT00985751
Locations
🇨🇿

GSK Investigational Site, Znojmo, Czechia

Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: Fluarix™
Biological: Influenza vaccine GSK2321138A
First Posted Date
2009-09-28
Last Posted Date
2018-09-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
599
Registration Number
NCT00985790
Locations
🇲🇽

GSK Investigational Site, Mexico city, Mexico

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: GSK2340273A
Biological: GSK2340274A
Biological: Seasonal trivalent influenza vaccine (TIV)
Biological: Saline placebo
First Posted Date
2009-09-28
Last Posted Date
2018-08-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
611
Registration Number
NCT00985673
Locations
🇨🇦

GSK Investigational Site, Sherbrooke, Quebec, Canada

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: GSK2340274A
Biological: GSK2340273A
Biological: Saline placebo
First Posted Date
2009-09-28
Last Posted Date
2017-12-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1343
Registration Number
NCT00985088
Locations
🇨🇦

GSK Investigational Site, Pointe-Claire, Quebec, Canada

Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination

Phase 4
Completed
Conditions
Hepatitis B
Interventions
Biological: Engerix™-B Kinder
First Posted Date
2009-09-25
Last Posted Date
2018-08-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
306
Registration Number
NCT00984139
Locations
🇩🇪

GSK Investigational Site, Berlin, Germany

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
First Posted Date
2009-09-25
Last Posted Date
2018-08-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
366
Registration Number
NCT00984659
Locations
🇺🇸

GSK Investigational Site, Spokane, Washington, United States

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Phase 3
Completed
Conditions
Embolism, Pulmonary
Interventions
First Posted Date
2009-09-22
Last Posted Date
2016-12-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
41
Registration Number
NCT00981409
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

Phase 3
Completed
Conditions
Influenza
Interventions
Biological: GSK2340273A
Biological: GSK2340274A
First Posted Date
2009-09-18
Last Posted Date
2018-03-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
4048
Registration Number
NCT00979602
Locations
🇨🇦

GSK Investigational Site, Quebec, Canada

Efficacy and Safety Study in Subjects With Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Dose 2 QD
Drug: Dose 3 QD
Drug: placebo
Drug: Dose 1 BD
Drug: Dose 4 QD
First Posted Date
2009-09-18
Last Posted Date
2017-01-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
75
Registration Number
NCT00980200
Locations
🇺🇸

GSK Investigational Site, Boerne, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy